MY206964A - Tricyclic akr1c3 dependent kars inhibitors - Google Patents
Tricyclic akr1c3 dependent kars inhibitorsInfo
- Publication number
- MY206964A MY206964A MYPI2021006666A MYPI2021006666A MY206964A MY 206964 A MY206964 A MY 206964A MY PI2021006666 A MYPI2021006666 A MY PI2021006666A MY PI2021006666 A MYPI2021006666 A MY PI2021006666A MY 206964 A MY206964 A MY 206964A
- Authority
- MY
- Malaysia
- Prior art keywords
- kars
- tricyclic
- inhibitors
- akr1c3
- dependent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor. The most suitable drawing: FIG. 1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881619P | 2019-08-01 | 2019-08-01 | |
| US202063009513P | 2020-04-14 | 2020-04-14 | |
| US202063033932P | 2020-06-03 | 2020-06-03 | |
| PCT/IB2020/057285 WO2021005586A1 (en) | 2019-08-01 | 2020-07-31 | Tricyclic akr1c3 dependent kars inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY206964A true MY206964A (en) | 2025-01-22 |
Family
ID=71994691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021006666A MY206964A (en) | 2019-08-01 | 2020-07-31 | Tricyclic akr1c3 dependent kars inhibitors |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US11970497B2 (en) |
| EP (2) | EP4013500B1 (en) |
| JP (1) | JP7008161B2 (en) |
| KR (1) | KR102735388B1 (en) |
| CN (1) | CN114206870B (en) |
| AU (1) | AU2020309846B2 (en) |
| BR (1) | BR112022001308A2 (en) |
| CA (1) | CA3139940A1 (en) |
| CL (1) | CL2022000201A1 (en) |
| CO (1) | CO2022000370A2 (en) |
| CR (1) | CR20220031A (en) |
| CU (1) | CU24698B1 (en) |
| DK (1) | DK4013500T3 (en) |
| DO (1) | DOP2022000010A (en) |
| EC (1) | ECSP22005621A (en) |
| ES (1) | ES2969591T3 (en) |
| FI (1) | FI4013500T3 (en) |
| HR (1) | HRP20231734T1 (en) |
| HU (1) | HUE064882T2 (en) |
| IL (1) | IL287792B2 (en) |
| JO (1) | JOP20220020B1 (en) |
| LT (1) | LT4013500T (en) |
| MA (1) | MA71308A (en) |
| MX (1) | MX2022000961A (en) |
| MY (1) | MY206964A (en) |
| PE (1) | PE20220343A1 (en) |
| PH (1) | PH12022550200A1 (en) |
| PL (1) | PL4013500T3 (en) |
| PT (1) | PT4013500T (en) |
| PY (1) | PY2039449A (en) |
| RS (1) | RS65068B1 (en) |
| SA (1) | SA522431533B1 (en) |
| SI (1) | SI4013500T1 (en) |
| TW (1) | TWI864063B (en) |
| UY (1) | UY38806A (en) |
| WO (1) | WO2021005586A1 (en) |
| ZA (1) | ZA202108632B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| JP7667097B2 (en) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ.ベー. | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators - Patents.com |
| UY38806A (en) | 2019-08-01 | 2021-02-26 | Novartis Ag | AKR1C3-DEPENDENT KARS TRICYCLIC INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES |
| IL300833A (en) | 2020-09-02 | 2023-04-01 | Ascentawits Pharmaceuticals Ltd | Akr1c3 detection method, and diagnostic kit for detecting akr1c3 and use thereof |
| CN113135878A (en) * | 2021-04-09 | 2021-07-20 | 新沂市凯美斯特医药科技有限公司 | Method for synthesizing 3-aminomethyl tetrahydrofuran by taking furan as raw material |
| PT4334289T (en) | 2021-05-07 | 2025-09-01 | Organon R&D Finland Oy | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof |
| CN115403579A (en) * | 2021-05-27 | 2022-11-29 | 上海拓界生物医药科技有限公司 | Novel spiro derivative and application thereof |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| CN118804755A (en) * | 2022-06-10 | 2024-10-18 | 深圳艾欣达伟医药科技有限公司 | Methods of treating cancer patients with AKR1C3 enzyme-activated prodrugs |
| CN119421704A (en) | 2022-07-26 | 2025-02-11 | 诺华股份有限公司 | Pharmaceutical composition of tricyclic AKR1C3-dependent KARS inhibitor and preparation method thereof |
| US20260007654A1 (en) | 2022-07-26 | 2026-01-08 | Novartis Ag | Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention |
| JP2025524064A (en) | 2022-07-26 | 2025-07-25 | ノバルティス アーゲー | Crystalline forms of AKR1C3-dependent KARS inhibitors |
| KR20260020475A (en) | 2023-06-06 | 2026-02-11 | 아센타위츠 파마슈티컬즈 리미티드 | Correlation between AKR1C3 enzyme expression levels and KRAS mutations and their medical applications. |
| CN121985960A (en) | 2023-10-18 | 2026-05-05 | 深圳艾欣达伟医药科技有限公司 | Treatment of patients with negative P53 gene mutation, positive KRAS gene mutation, and positive BRCA mutation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476019B1 (en) * | 1999-08-13 | 2002-11-05 | Sepracor Inc. | Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof |
| WO2006023821A2 (en) * | 2004-08-20 | 2006-03-02 | The Trustees Of Columbia University In The City Of New York | Ligands for aldoketoreductases |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| UY33779A (en) * | 2010-12-10 | 2012-07-31 | Boehringer Ingelheim Int | ? 2- (Phenylamino) -1H-benzimidazol-5-carboxamides novel? |
| US9346803B2 (en) * | 2011-10-17 | 2016-05-24 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| WO2016145092A1 (en) | 2015-03-10 | 2016-09-15 | Threshold Pharmaceuticals, Inc. | Dna alkylating agents |
| US10167293B2 (en) * | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
| CN113226464A (en) * | 2018-12-18 | 2021-08-06 | 诺华股份有限公司 | N- (pyridin-2-ylsulfonyl) cyclopropanecarboxamide derivatives and their use in the treatment of CFTR mediated diseases |
| UY38806A (en) * | 2019-08-01 | 2021-02-26 | Novartis Ag | AKR1C3-DEPENDENT KARS TRICYCLIC INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES |
-
2020
- 2020-07-27 UY UY0001038806A patent/UY38806A/en not_active Application Discontinuation
- 2020-07-27 PY PY202002039449A patent/PY2039449A/en unknown
- 2020-07-30 TW TW109125732A patent/TWI864063B/en active
- 2020-07-31 DK DK20753456.1T patent/DK4013500T3/en active
- 2020-07-31 IL IL287792A patent/IL287792B2/en unknown
- 2020-07-31 AU AU2020309846A patent/AU2020309846B2/en active Active
- 2020-07-31 PT PT207534561T patent/PT4013500T/en unknown
- 2020-07-31 MY MYPI2021006666A patent/MY206964A/en unknown
- 2020-07-31 JP JP2021507653A patent/JP7008161B2/en active Active
- 2020-07-31 HU HUE20753456A patent/HUE064882T2/en unknown
- 2020-07-31 CN CN202080053804.1A patent/CN114206870B/en active Active
- 2020-07-31 FI FIEP20753456.1T patent/FI4013500T3/en active
- 2020-07-31 SI SI202030346T patent/SI4013500T1/en unknown
- 2020-07-31 CR CR20220031A patent/CR20220031A/en unknown
- 2020-07-31 PL PL20753456.1T patent/PL4013500T3/en unknown
- 2020-07-31 PE PE2022000125A patent/PE20220343A1/en unknown
- 2020-07-31 MX MX2022000961A patent/MX2022000961A/en unknown
- 2020-07-31 LT LTEPPCT/IB2020/057285T patent/LT4013500T/en unknown
- 2020-07-31 CU CU2022000005A patent/CU24698B1/en unknown
- 2020-07-31 ES ES20753456T patent/ES2969591T3/en active Active
- 2020-07-31 MA MA71308A patent/MA71308A/en unknown
- 2020-07-31 WO PCT/IB2020/057285 patent/WO2021005586A1/en not_active Ceased
- 2020-07-31 EP EP20753456.1A patent/EP4013500B1/en active Active
- 2020-07-31 US US16/973,836 patent/US11970497B2/en active Active
- 2020-07-31 RS RS20240042A patent/RS65068B1/en unknown
- 2020-07-31 KR KR1020227002658A patent/KR102735388B1/en active Active
- 2020-07-31 CA CA3139940A patent/CA3139940A1/en active Pending
- 2020-07-31 EP EP23195635.0A patent/EP4349839A3/en active Pending
- 2020-07-31 HR HRP20231734TT patent/HRP20231734T1/en unknown
- 2020-07-31 PH PH1/2022/550200A patent/PH12022550200A1/en unknown
- 2020-07-31 BR BR112022001308A patent/BR112022001308A2/en unknown
-
2021
- 2021-11-04 ZA ZA2021/08632A patent/ZA202108632B/en unknown
-
2022
- 2022-01-18 CO CONC2022/0000370A patent/CO2022000370A2/en unknown
- 2022-01-20 DO DO2022000010A patent/DOP2022000010A/en unknown
- 2022-01-24 EC ECSENADI20225621A patent/ECSP22005621A/en unknown
- 2022-01-25 CL CL2022000201A patent/CL2022000201A1/en unknown
- 2022-01-25 JO JOJO/P/2022/0020A patent/JOP20220020B1/en active
- 2022-01-29 SA SA522431533A patent/SA522431533B1/en unknown
-
2024
- 2024-03-04 US US18/594,323 patent/US20240262827A1/en not_active Abandoned
-
2025
- 2025-01-31 US US19/042,086 patent/US20250179072A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522431533B1 (en) | Tricyclic akr1c3 dependent kars inhibitors | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| PH12017500583B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| SA518392101B1 (en) | Benzimidazole Derivatives as Modulators of ROR-GAMMA | |
| MX2018006223A (en) | Modulators of ror-gamma. | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| EP4520395A3 (en) | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| MY209035A (en) | Tricyclic compounds and their use | |
| PH12021550901A1 (en) | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | |
| WO2016178092A3 (en) | C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors | |
| EA202191955A1 (en) | MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS | |
| MX2023005076A (en) | Interleukin-17 inhibitors. | |
| WO2017134685A3 (en) | Novel hydrazino compounds as btk inhibitors | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| MX379327B (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| ZA202100955B (en) | Thrombin inhibitors, formulations, and uses thereof | |
| EA201992151A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY |